Proactive therapeutic drug monitoring of infliximab leads to durability of treatment in children with Inflammatory Bowel Disease

被引：0
|
作者：
Chuah, C. W. [1 ]
Eldredge, J. [1 ]
Magoffin, A. [1 ]
O'Loughlin, E., V [1 ]
Park, C. J. [2 ]
Puppi, J. [1 ]
Siew, S. [1 ,3 ]
Stormon, M. [1 ]
Thacker, K. [1 ]
Dutt, S. [1 ,3 ]
机构：
[1] Childrens Hosp Westmead, Dept Gastroenterol, Westmead, Australia
[2] Australian Natl Univ, Sydney Adventist Hosp, Clin Sch, Sch Med & Psychol, Canberra, Australia
[3] Univ Sydney, Childrens Hosp Westmead Clin Sch, Sydney Sch Med, Sydney, Australia
来源：
JOURNAL OF CROHNS & COLITIS | 2025年 / 19卷
关键词：
D O I：
10.1093/ecco-jcc/jjae190.1321
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
P1147
引用
收藏
页码：i2099 / i2099
页数：1
相关论文
共 50 条
  • [1] Proactive therapeutic drug monitoring (TDM) of infliximab leads to durability of treatment in children with inflammatory bowel disease
    Chuah, Cher Wei
    Dutt, Shoma
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2024, 39 : 325 - 325
  • [2] Therapeutic drug monitoring in 45 children with inflammatory bowel disease on maintenance infliximab treatment
    Rolandsdotter, H.
    Marits, P.
    Sundin, U.
    Wikstrom, A. -C.
    Fagerberg, U.
    Finkel, Y.
    Eberhardson, M.
    JOURNAL OF CROHNS & COLITIS, 2016, 10 : S363 - S364
  • [3] Early proactive therapeutic drug monitoring program for management of infliximab in inflammatory bowel disease: long-term durability of treatments
    Sanchez-Hernandez, J. G.
    Rebollo, N.
    Munoz, F.
    Saez-Fernandez, E. M.
    Rodriguez-Rodriguez, G.
    Tapia-Artiles, C.
    Fernandez-Caballero, R.
    Calvo, M. V.
    INTERNATIONAL JOURNAL OF CLINICAL PHARMACY, 2020, 42 (01) : 232 - 233
  • [4] Longer Duration of Response With Proactive Therapeutic Drug Monitoring for Infliximab but Not for Vedolizumab Treatment in Patients With Inflammatory Bowel Disease
    Al Yassin, Sarmed
    Spataro, Joseph
    Kang, Le
    Gaidos, Jill
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2020, 115 : S359 - S359
  • [5] Proactive Therapeutic Drug Monitoring in Pediatric Inflammatory Bowel Disease Patients Receiving Infliximab and Biosimilars
    Aktay, Atiye
    Odolil, Abel
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2024, 119 (12S): : S21 - S21
  • [6] COST EFFECTIVENESS OF A PROACTIVE THERAPEUTIC DRUG MONITORING STRATEGY IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE RECEIVING INFLIXIMAB
    Doherty, Jayne
    Varley, Rachel
    Kennedy, Una
    Healy, Martin
    Dunne, Cara
    Maccarthy, Finbar
    Mckiernan, Susan
    Hartery, Karen
    Kevans, David
    GASTROENTEROLOGY, 2021, 160 (06) : S692 - S693
  • [7] Proactive therapeutic infliximab monitoring during induction phase in inflammatory bowel disease
    Gonzalez Vivo, M.
    Carballo Martinez, N.
    Padulles Zamora, N.
    Colominas Gonzalez, E.
    Murciano Gonzalo, F.
    Abril Rodriguez, L.
    Marquez-Mosquera, L.
    JOURNAL OF CROHNS & COLITIS, 2023, 17 : 842 - 843
  • [8] Cost Effectiveness of a Proactive Therapeutic Drug Monitoring Strategy in Patients with Inflammatory Bowel Disease Receiving Infliximab
    Doherty, J.
    Varley, R.
    Healy, M.
    Dunne, C.
    Mac Carthy, E.
    Mc Kiernan, S.
    Hartery, K.
    Kevans, D.
    JOURNAL OF CROHNS & COLITIS, 2021, 15 : S445 - S446
  • [9] Proactive therapeutic drug monitoring and vedolizumab dose optimization in children with inflammatory bowel disease
    Rowland, Patrick
    Mcnicol, Megan
    Kiel, Ashley
    Maltz, Ross M.
    Donegan, Amy
    Dotson, Jennifer L.
    Michel, Hilary K.
    Boyle, Brendan
    JOURNAL OF PEDIATRIC GASTROENTEROLOGY AND NUTRITION, 2024, 78 (04): : 853 - 861
  • [10] Proactive infliximab drug monitoring is superior to conventional management in inflammatory bowel disease
    Raimundo Fernandes, S.
    Bernardo, S.
    Simoes, C.
    Correia, L.
    Moura Santos, P.
    Rita Goncalves, A.
    Valente, A.
    Baldaia, C.
    Tato Marinho, R.
    JOURNAL OF CROHNS & COLITIS, 2019, 13 : S64 - S65
12345